Back

FH genotype stratifies LDL-C–lowering response and improves diagnostic discrimination in severe hypercholesterolemia

31 August 2026 (12:48 - 13:00)
Organised by: Logo
Congress Presentation Part of: Lipids and myocardial infarction Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Johannes Bernhard

Medical University of Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail
Lipoprotein(a), smoking, and diabetes are additive, but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome: An analysis of the ODYSSEY OUTCOMES trial
Professor G. Schwartz (Aurora, US)
Abstract Slides
Presentation thumbnail
Sex differences in lipid management among high-risk patients without prior myocardial infarction or stroke: results from the VESALIUS-REAL global study
Associate Professor E. Hagstrom (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial
Doctor F. Wang (Beijing, CN)
Abstract Slides
Presentation thumbnail
Extreme HDL-C associated increased mortality is explained by confounding due to progressively increasing alcohol-induced multisystem morbidity
Doctor B. Ference (Cambridge, GB)
Abstract Slides

Access the full session

Session thumbnail
Lipids and myocardial infarction
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 12:48 CET
You may be interested in
thumbnail
Congress Presentation
Comparison of severe hypercholesterolemia patients with and without pathogenic variants
28 August 2022
thumbnail
Congress Presentation
The current LDL-C target <1.4mmol/l of the ESC is achieved in less than 16% of patients with Coronary Heart Disease despite effective lipid-lowering therapy: Data from the LLT-R registry
28 August 2020
thumbnail
Congress Presentation
Triglyceride-associated markers and genetic variants of eNOS3 in the stratification of residual cardiorenal risk in patients with arterial hypertension and diabetic nephropathy
24 April 2026
thumbnail
Congress Presentation
Effect of SLCO1B1 genotypes on statin intolerance and response to statins
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources